Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early‐onset Alzheimer's disease

Abstract Introduction People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods Noradrenaline, adrenaline, and their metabolite 3‐methoxy‐4‐hydr...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Alain D. Dekker, Yannick Vermeiren, Maria Carmona‐Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean‐Jacques Martin, Netherlands Brain Bank, Rafael Blesa, Juan Fortea, Peter P. De Deyn
Format: Artigo
Jezik:Inglês
Izdano: Wiley 2018-01-01
Serija:Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
Teme:
Alzheimer's disease
Cerebrospinal fluid
Dementia
Dopamine
Down syndrome
Monoamines
Online pristup:https://doi.org/10.1016/j.dadm.2017.11.001
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items